MorphoSys is acquiring Constellation Pharmaceuticals and its late-stage myelofibrosis drug in a deal that values the epigenetics biotech at $1.7 billion. Germany-based MorphoSys will finance the acquisition with cash from a separate $2 billion deal with drug royalty acquirer Royalty Pharma.
Kaia Health, a startup providing app-based programs for musculoskeletal conditions and COPD, recently raised $75 million in funding. As competitors look to round out their platforms with other services, Kaia is looking to strike partnerships with clinicians.
There are a number of criteria for selecting the best autism therapy centers. Parents choosing a facility or professionals seeking to improve their offerings should consider certain standards to ensure the right fit.
The FDA approved Monjuvi for second-line diffuse large B-cell lymphoma. Though the drug has the same antigen target as approved CAR-T cell therapies, it is designed for patients unable to tolerate such intensive treatments.
Kaia Health, a startup making an app to help users manage back pain, touted the results of a large, randomized controlled trial using its app. The company currently markets its system to employers, but hopes to make it available as a covered benefit in the future.
German medical technology company Brainlab acquired Level Ex, a startup that creates games for physicians. Level Ex's games allow physicians and surgeons to practice their skills in different scenarios, ranging from pulmonology to interventional cardiology.
The German biotech company said Monday it had applied for approval of tafasitamab in diffuse large B-cell lymphoma, which targets the same antigen as CAR-T, but would be for a population unable to tolerate the cell therapies.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
The German drugmaker plans to submit its data package for FDA approval by the end of the year, with potential approval next year. The package will include a synthetic control arm comprising real-world data.
Larotrectinib showed an 81 percent response rate among 109 patients with NTRK fusion-positive cancers, with most continuing to respond or receiving surgery with curative intent after more than a year.
Siemens did not indicate when the Healthineers IPO would take place, how much the company would try to raise or where shares would be listed.